Cargando…
S276: POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY-RELATED DISEASES
Autores principales: | Dillon, Stacey, Davies, Rupert, Lickliter, Jason, Mclendon, Kristi, Kristi L. Manjarrez, Kristi, Smith, Alina, Hudson, Krystalyn, Blanchfield, Lori, Sanderson, Russel, Chunyk, Allison, Blair, Tiffany, Enstrom, Amanda, Zayed, Hany, Peng, Stanford |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428452/ http://dx.doi.org/10.1097/01.HS9.0000968016.33010.55 |
Ejemplares similares
-
PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
por: Broome, Catherine M, et al.
Publicado: (2023) -
First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects
por: Yang, Jing, et al.
Publicado: (2021) -
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome
por: Kannel, Karin, et al.
Publicado: (2015) -
Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models
por: Orvain, Cindy, et al.
Publicado: (2022) -
Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial
por: Gonzalez-Miro, Majela, et al.
Publicado: (2023)